Rosas Paola C, Solaro R John
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Department of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Compr Physiol. 2025 Apr;15(2):e70006. doi: 10.1002/cph4.70006.
This review focuses on p21-activated kinase 1 (Pak1), a multifunctional, highly conserved enzyme that regulates multiple downstream effectors present in many tissues. Upstream signaling via Ras-related small G-proteins, Cdc42/Rac1 promotes the activity of Pak1. Our hypothesis is that this signaling cascade is an important element in communication among the myocardium, adipose tissue, and pancreatic β-cells. Evidence indicates that a shared property of these tissues is that structure/function stability requires homeostatic Pak1 activity. Increases or decreases in Pak1 activity may promote dysfunction or increase susceptibility to stressors. Evidence that increased levels of Pak1 activity may be protective provides support for efforts to develop therapeutic approaches activating Pak1 with potential use in prevalent disorders associated with obesity, diabetes, and myocardial dysfunction. On the other hand, since increased Pak1 activity is associated with cancer progression, there has been a significant effort to develop Pak1 inhibitors. These opposing therapeutic approaches highlight the need for a deep understanding of Pak1 signaling in relation to the development of effective and selective therapies with minimal or absent off-target effects.
本综述聚焦于p21激活激酶1(Pak1),这是一种多功能、高度保守的酶,可调节许多组织中存在的多种下游效应分子。通过Ras相关小G蛋白Cdc42/Rac1的上游信号传导可促进Pak1的活性。我们的假设是,这种信号级联是心肌、脂肪组织和胰腺β细胞之间通讯的重要元素。有证据表明,这些组织的一个共同特性是结构/功能稳定性需要稳态的Pak1活性。Pak1活性的增加或降低可能会促进功能障碍或增加对应激源的易感性。Pak1活性水平升高可能具有保护作用的证据,为开发激活Pak1的治疗方法提供了支持,这些方法可能用于治疗与肥胖、糖尿病和心肌功能障碍相关的常见疾病。另一方面,由于Pak1活性增加与癌症进展相关,人们一直在大力开发Pak1抑制剂。这些相反的治疗方法凸显了深入了解Pak1信号传导对于开发有效且选择性高、脱靶效应最小或无脱靶效应的疗法的必要性。